Chugai Signals Cell Therapy Interest Via Athersys Deal
This article was originally published in PharmAsia News
Executive Summary
The U.S. venture Athersys has entered into a cell therapy alliance with Chugai that will enable it to take advantage of the newly supportive regulatory environment in Japan for regenerative medicines and to access a potentially large market.